Home > News > Headline News > Archive

Click on title to read the full article.

Denosumab Superior for Bone Metastases, But of 'Debatable Value'

March 30, 2011

By Zosia Chustecka

More clinical trial data — from 2 pivotal studies — have been published showing that the novel bone-modifying drug denosumab (Xgeva, Amgen) is superior to zoledronic acid in preventing skeletal-related events (SREs) in cancer patients with bone metastases.

Interventional Radiologists Provide Hope in Delaying Growth, Spread of Breast Cancer

March 30, 2011

By The Society of Interventional Radiology

The growth and spread of breast cancer tumors may be delayed with a promising treatment that combines two innovative strategies: blocking the enzyme needed to "energize" cancer cells and infusing a potent drug directly into the tumor, with minimum exposure to healthy tissues, indicate researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

New Targets Found for Aggressive Breast Cancer

March 25, 2011

By /source Harvard Medical School

With currently available early-detection methods for breast cancer, many people can be treated successfully. But for the 20 percent of patients with so-called triple-negative breast cancer, the outcome is bleak. Now, however, researchers from Harvard Medical School and Baylor College of Medicine have identified a critical molecular component to the disease.

Can Biopsies of Liver Metastases Improve Treatment Choice?

March 23, 2011

By Anna Azvolinsky

Analyses of the levels of estrogen receptor (ER), progesterone(Drug information on progesterone) receptor (PgR), and human epidermal growth factor receptor 2 (HER2) are standard practice following an initial breast cancer diagnosis. This characterization is important to subtype the cancer and determines the choice of therapy.

Seven-Day On-Off Capecitabine Cycle Treats Breast Cancer

March 23, 2011

Treatment of metastatic breast cancer with capecitabine administered for seven days followed by seven days of rest in combination with bevacizumab has modest efficacy and minimal toxicity, as indicated by mathematical predictions, according to a study published online March 8 in Cancer.

Lifting the Fog

March 22, 2011

By Elaine Schattner

New research helps clarify chemobrain.

Revised Guidelines on Metastatic Breast Cancer Bone Metastases

March 22, 2011

By Anne Azvolinsky, PhD

The American Society of Clinical Oncology (ASCO) updated its recommendation last month on the role of bone-modifying agents in the prevention of skeletal-related events (SREs) for metastatic breast cancer patients with bone metastases

Primary tumour excision in metastatic breast cancer impacts on survival

March 21, 2011

By Janet Fricker

Operating on patients with metastatic breast cancer to reduce their total tumour burden improves overall survival, reports a Pakistani abstract at the International Breast Cancer Conference (St Gallen, Switzerland, 16-19 March).

Hurdles on the Faster Track

March 21, 2011

By Mike King

Patients & the FDA struggle over how to define success in the battle against metastatic disease.

Marking a New Pathway for Hormone-Resistant Breast Cancer Treatment

March 18, 2011

By Lois Wingerson

The PI3K pathway receives plenty of hopeful attention as an alternative for ER+ patients in whom hormonal therapy has come to a dead end, with aromatase inhibitor resistance.

 1 2 >